Showing posts with label who. Show all posts
Showing posts with label who. Show all posts

Saturday, 11 November 2017

WHAT CAN WE DO TO CONTROL ANTIBIOTIC RESISTANCE?

WHAT CAN WE DO TO CONTROL ANTIBIOTIC RESISTANCE?

Draft for ‘Indian Medical Association (IMA) Policy on Use of Antibiotics’ to be discussed at the Antimicrobial Resistance Conference supported by the World Health Organization (WHO) on November 11, 2017

Following are the issues to be discussed today to finalize and formulate IMA Policy with regard to use of antibiotics in order to control antibiotic resistance.

·         Antibiotic consent:Patients often demand antibiotics even when the doctor thinks it is unnecessary. ‘Antibiotic consent’ should be a part of the informed consent process, so that the patient is aware of the benefits and risks of antibiotics.

  • If you have prescribed antibiotics, put the name of the antibiotic in a box/underline it, so that patient can identify the antibiotic in his/her prescription

  • Write the total number of antibiotic tablets/capsules to be taken for the prescribed duration in the prescription and not just the dose administration schedule

·         Consider shifting Schedule H and H1 drugs to Schedule X

·         Antibiotic tax like sugar tax to prevent their overuse and also the money earned via tax on antibiotics can fund research into antibiotic resistance and/or development of new antibiotics

·         All food products should be labeled “Antibiotic free”.Antibiotic resistance is also a concern with regard to food safety. The bacteria that contaminate food can be resistant because of the use of antibiotics in people and for growth promotion or disease prevention in healthy food-producing animals.

·         Antibiotic waste disposal policy to prevent contamination of the environment; discharge of untreated waste into soil and rivers is leading to spread of antibiotic resistance

·         Before prescribing antibiotic, always ask yourself
o    Is it necessary?
o    What is the most effective antibiotic?
o    What is the most affordable antibiotic?
o    What is the most effective dose?
o    What is the most effective duration for which the antibiotic should be administered?













Other Strategies to combat Antibiotic Resistance

  • Practice rational use of drugs (antibiotics)

o    Use when needed and according to guidelines
o    Avoid broad spectrum antibiotics without appropriate diagnosis

·         Prevent infections with the use of vaccination and by improving basic hygiene, including hand hygiene and infection control techniques and sanitation in health care settings as well as in the community

·         Farmers and food industry must stop using antibiotics routinely to promote growth and prevent disease in healthy animals to prevent the spread of antibiotic resistance. New “WHO guidelines on use of medically important antimicrobials in food-producing animals” released November 7, 2017 aim to help preserve the effectiveness of antibiotics that are important for human medicine by reducing their unnecessary use in animals. “Healthy animals should only receive antibiotics to prevent disease if it has been diagnosed in other animals in the same flock, herd, or fish population. Where possible, sick animals should be tested to determine the most effective and prudent antibiotic to treat their specific infection.”

·         One health approach, which recognizes that the health of people is connected to the health of animals and the environment. The goal is to achieve the best health for people, animals, and our environment through collaborative efforts of multiple stakeholders

  • India’s‘National Action Plan on Antimicrobial Resistance (NAP-AMR) 2017 – 2021’, was launched at the ‘Inter-Ministerial Consultation on antimicrobial resistance (AMR)containment in April 2017. The Ministry of Health & Family Welfare has identified AMR as one of the top 10 priorities for the ministry’s collaborative work with WHO.

A ‘Delhi Declaration’ (http://cseindia.org/userfiles/delhi_declaration_20170420.pdf), an inter-ministerial consensus released at the conclusion of this meeting pledged to adopt a holistic and collaborative approach towards prevention and containment of AMR in India.

Six strategic priorities have been identified under the NAP-AMR

                     i.        improving awareness and understanding of AMR through effective communication, education and training;
                    ii.        strengthening knowledge and evidence through surveillance;
                   iii.        reducing the incidence of infection through effective infection prevention and control;
                   iv.        optimizing the use of antimicrobial agents in health, animals and food;
                    v.        promoting investments for AMR activities, research and innovations; and
                   vi.        strengthening India’s leadership on AMR

  • Changing over to etiology based treatment of infections rather than a syndromic management.

Data from 77 countries show that antibiotic resistance is making gonorrhoea – a common sexually-transmitted infection – much harder, and sometimes impossible, to treat. The WHO Global Gonococcal Antimicrobial Surveillance Programme (WHO GASP) data from 2009 to 2014 find widespread resistance to ciprofloxacin (97% of countries that reported data in that period found drug-resistant strains), increasing resistance to azithromycin (81%), and the emergence of resistance to the current last-resort treatment: the extended-spectrum cephalosporins (ESCs) oral cefixime or injectable ceftriaxone (66%) (WHO News Release, July 7, 2017).

  • Ensure universal health coverage

  • New guidelines to be formulated taking into consideration the existing local, regional and national resistance and susceptibility data in the country

  • Hospital antibiotic policy should be formulated based on local susceptibility patterns

  • Reporting of antibiotic-resistant infections to surveillance groups to strengthen knowledge through surveillance and research

  • Educating the patients and the general public about the dangers of misuse or noncompliance to antibiotic






































Background: About Antibiotic Resistance

The prevalence of antibiotic resistance is escalating worldwide at an alarming pace, with not enough resources available to control it. The WHO has recognized antibiotic resistance as a significant public health problem in its first global report “Antimicrobial resistance: Global report on surveillance” released in 2014.

No age group is exempt from antibiotic resistance. A retrospective study published in the March 2017 issue of the Journal of the Pediatric Infectious Diseases Society observed 700% increase in multidrug-resistant Gram-negative enteric Enterobacteriaceae infections between January 1, 2007, and March 31, 2015.1

Its impact on patients and communities are well-known. Antibiotic resistance has made it difficult to treat many infections such as TB, typhoid, pneumonia, gonorrhea. Antibiotic resistance also increases hospitalization duration, adverse drug reactions, therapeutic failure and associated mortality. When infections become resistant to first-line antibiotics, then second- or third-line drugs, which are costly resulting in increased costs of treatment. 2 These drugs may also be less effective and have more side effects.

We are on the verge of a post-antibiotic era where many of the antibiotics to which bacteria have developed resistance may become obsolete and there may no longer be any cure for many common infections, which once again may take their toll on human life like in the pre-penicillin era.

In its global report, the WHO has also cautioned about the likelihood of post-antibiotic era stating, “A post-antibiotic era—in which common infections and minor injuries can kill—far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century”.

This year, WHO published its first ever list of antibiotic-resistant "priority pathogens", which included 12 classes of bacteria (as below) in addition to multidrug-resistant tuberculosis that pose the greatest threat to human health. These pathogens are increasingly becoming resistant to existing antibiotics and urgently in need of new treatments. (WHO News Release, February 2, 2017)

WHO list of antibiotic-resistant priority pathogens

Priority 1: Critical

·         Acinetobacter baumannii, carbapenem-resistant
·         Pseudomonas aeruginosa, carbapenem-resistant
·         Enterobacteriaceae, carbapenem-resistant, ESBL-producing

Priority 2: High

·         Enterococcus faecium, vancomycin-resistant
·         Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant
·         Helicobacter pylori, clarithromycin-resistant
·         Campylobacter spp., fluoroquinolone-resistant
·         Salmonellae, fluoroquinolone-resistant
·         Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant

Priority 3: Medium

·         Streptococcus pneumoniae, penicillin-non-susceptible
·         Haemophilus influenzae, ampicillin-resistant
·         Shigella spp., fluoroquinolone-resistant


Factors contributing to antibiotic resistance

The major factor determining antibiotic resistance is use of antibiotics. But, there are several other factors, which also influence the emergence of antibiotic resistance.

  • Overprescribing of antibiotics
o    Patient pressure
o    Peer pressure

  • Inappropriate prescribing of antibiotics: Wrong drug, wrong doses, or antibiotic not required

o    Prescribing antibiotics in viral infections like the common cold, flu, diarrhea

o    Prescribing subtherapeutic doses of antibiotics: In a pilot cross-sectional study Saleh et al, the prescribed dose and the duration of the treatment were inaccurate in 52% and 64% of the cases, respectively. 3

o    Administering broad-spectrum antibiotics without a definitive diagnosis and indication for antimicrobial treatment. 4

o    Prescribing antibiotics in fungal infection due to incorrect diagnosis: A study published February 2017 issue of CDC’s journal Emerging Infectious Diseases concluded that “the lack of availability and underuse of nonculture fungal diagnostics results in overprescribing, prescription of unduly long courses of antibacterial agents, and excess empirical use of antifungal agents and leaves many millions of patients with undiagnosed fungal infections”. 5

This study also cited four common clinical situations, where lack of routine diagnostic testing for fungal diseases often worsens the problem.

§  Inaccurate diagnosis of fungal sepsis in hospitals and intensive care units, resulting in inappropriate use of broad-spectrum antibacterial drugs in patients with invasive candidiasis.
§  Failure to diagnose chronic pulmonary aspergillosis in patients with smear-negative pulmonary tuberculosis.
§  Misdiagnosis of fungal asthma, resulting in unnecessary treatment with antibacterial drugs instead of antifungal drugs and missed diagnoses of life-threatening invasive aspergillosis in patients with chronic obstructive pulmonary disease.
§  Overtreatment and undertreatment of Pneumocystis pneumonia in HIV-positive patients.

  • Relying on syndromic approach to manage infections instead of evidence-based prescribing.4

  • Noncompliance and self-medication by patients

  • Patients not completing the entire antibiotic course; missing doses, either by accident or deliberate

  • Antibiotic misuse due to their availability over the counter, without prescription and through unregulated supply chains

  • Poor hygiene and lack of compliance with infection prevention and control measures have contributed to the propagation and spread of resistant bacteria strains. 6

  • Overuse of antibiotics as additives in agriculture and as growth supplements in livestock and in aquaculture. The resistant bacteria in animals can spread to humans through the consumption of food or through direct contact with food-producing animals or through environmental spread (e.g. human sewage and runoff water from agricultural sites). 4

  • Availability of very few new antibiotics is another factor that has contributed to antibiotic resistance. A report released in September 2017 by WHO “Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis” shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance. Most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions.

Teixobactin, the first in a new class of antibiotics produced by soil microorganism (provisionally named Eleftheria terrae) has been reported. It is the first antibiotic to be discovered in three decades and is still in at an early stage of development.  Teixobactin has activity against Gram-positive (but not Gram-negative) organisms and mycobacteria and a novel mode of action inhibiting peptidoglycan biosynthesis. 7

  • The role of environment in the spread of antibiotic resistance is now being recognized. 2

o    Soil is a reservoir of antibiotic resistance genes, since most antibiotics are derived from soil microorganisms that are intrinsically resistant to the antibiotics produced. Soil also receives a large portion of excreted antibiotics through application of manure and sewage sludge as fertilizers. 6
o    Antibiotic-resistant organisms can also spread via drinking water derived from surface water sources. 6Large amounts of antibiotics are released into municipal wastewater due to incomplete metabolism in human beings or due to disposal of unused antibiotics. 2 Evidence suggests that the conventional wastewater treatment process is inadequate in removing resistant bacteria from municipal wastewater. 6Exposure to dairy manure alters soil microbial communities and ecosystem function and leads to greater antibiotic resistance. 8

References

1.    Meropol SB, Haupt AA, Debanne SM. Incidence and outcomes of infections caused by multidrug-resistant Enterobacteriaceae in children, 2007-2015. J Pediatric Infect Dis Soc. 2017 Feb 22.

2.    Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309-18.

3.    Saleh N, Awada S, Awwad R, et al. Evaluation of antibiotic prescription in the Lebanese community: a pilot study. Infect Ecol Epidemiol. 2015;5:27094.

4.    Ayukekbong JA, Ntemgwa M, Atabe AN.  The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob Resist Infect Control. 2017;6:47.

5.    Denning DW, Perlin DS, Muldoon EG, et al. Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities. Emerg Infect Dis. 2017;23(2):177-83.

6.    Fletcher S. Understanding the contribution of environmental factors in the spread of antimicrobial resistance. Environ Health Prev Med. 2015;20(4):243-52.

7.    Piddock LJ. Teixobactin, the first of a new class of antibiotics discovered by iChip technology? J Antimicrob Chemother. 2015;70(10):2679-80.


8.    Wepking C, Avera B, Badgley B, et al. Exposure to dairy manure leads to greater antibiotic resistance and increased mass-specific respiration in soil microbial communities. Proc Biol Sci. 2017;284(1851). 

Monday, 29 May 2017

WHO confirms three Zika cases in India

WHO confirms three Zika cases in India The first three cases of Zika virus infection were confirmed on Friday from Ahmedabad, Gujarat by the World Health Organization (WHO). In its report dated May 26, 2017, the WHO said, “On 15 May 2017, the Ministry of Health and Family Welfare-Government of India (MoHFW) reported three laboratory-confirmed cases of Zika virus disease in Bapunagar area, Ahmedabad District, Gujarat, State, India. The routine laboratory surveillance detected a laboratory-confirmed case of Zika virus disease through RT-PCR test at B.J. Medical College, Ahmedabad, Gujarat. The etiology of this case has been further confirmed through a positive RT-PCR test and sequencing at the national reference laboratory, National Institute of Virology (NIV), Pune on 4 January 2017 (case 2, below). Two additional cases (case 1 and case 3), have then been identified through the Acute Febrile Illness (AFI) and the Antenatal clinic (ANC) surveillance." (Source: WHO, May 26, 2017) Zika virus disease was declared as a Public Health Emergency of International Concern (PHEIC) by the WHO in February last year. And, in November 2016, the WHO declared an end to its global health emergency over the spread of the Zika virus. Guidelines on the Zika virus disease were issued by the Ministry of Health and Family Welfare last year. NCDC, Delhi and National Institute of Virology (NIV), Pune were designated as the apex laboratories to support the outbreak investigation and for confirmation of laboratory diagnosis. According to the WHO report, an Inter-Ministerial Task Force has been set up under the Chairmanship of Secretary (Health and Family Welfare) together with Secretary (Bio-Technology), and Secretary (Department of Health Research). The Joint Monitoring Group, a technical group tasked to monitor emerging and re-emerging diseases is regularly reviewing the global situation on Zika virus disease. In addition to National Institute of Virology, Pune, and NCDC in Delhi, 25 laboratories have also been strengthened by Indian Council of Medical Research for laboratory diagnosis. In addition, 3 entomological laboratories are conducting Zika virus testing on mosquito samples. The Indian Council of Medical Research (ICMR) has tested 34 233 human samples and 12 647 mosquito samples for the presence of Zika virus. Among those, close to 500 mosquitoes samples were collected from Bapunagar area, Ahmedabad District, in Gujarat, and were found negative for Zika. However, this report has highlighted India’s vulnerability to vector-borne diseases due to its huge population, climate and people traveling into the country in large numbers. These cases provide evidence on the circulation of the virus in India suggesting low level transmission of Zika virus and chances of more cases occurring. Dengue and Chikungunya are already endemic in the country. All these three diseases – Dengue, Chikungunya and Zika – are viral infections and share a common vector, the Aedes mosquitoes. Dengue or Chikungunya-like symptoms with red eyes, fever with a rash or joint pain should not be ignored. Such cases could be Zika. Eliciting a travel history in such patients is very important. There is no specific treatment. Patients should be advised to take paracetamol to relieve fever and pain, plenty of rest and plenty of liquids. Aspirin, products containing aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen should be avoided. In view of the detection of Zika in India, the need of the hour is enhanced surveillance: community-based and at international airports and ports to track cases of acute febrile illness. While awareness needs to be created about the disease, the public needs to be reassured that there is no cause for undue concern. There is no vaccine for Zika virus infection. Protection against mosquito bites is very important to prevent Zika infection. People traveling to high risk areas, especially pregnant women, should take protections from mosquito bites. • Stay inside when the Aedes are most active. They bite during the daytime, in the very early morning, and in the few hours before sunset. • Buildings with screens and air conditioning are safest. • Wear shoes, long-sleeved shirts, and long pants when you go outside. • Ensure that rooms are fitted with screens to prevent mosquitoes from entering. • Wear bug spray or cream that contains DEET or a chemical called picaridin. Dr KK Aggarwal National President IMA & HCFI

Thursday, 4 May 2017

Tuberculosis still a cause for concern

Tuberculosis still a cause for concern About 45% of the multi-drug cases are from India and two other countries New Delhi, 03 May 2017: According to a report by WHO, India has 27% of the world's new tuberculosis (TB) cases. TB is one of the biggest infectious diseases in India. The country accounts for a high number of worldwide TB cases due to which the global estimates have also gone up from 9.6 million to 10.4 million. Apart from this, about 2.5% of the new TB cases are resistant to Rifampicin, or to both Rifampicin and Isoniazid, the two most commonly used anti-TB drugs. About 45% of the multi-drug resistant TB cases in the world are from India, China, and the Russian Federation. Although TB is treatable, treatment reaches only 59% of the estimated TB patients in India. This is due to the fact that many people in different regions of India still do not fall under the ambit of the government's TB programme. Speaking about this, Padma Shri Awardee Dr K K Aggarwal, National President Indian Medical Association (IMA) and President Heart Care Foundation of India (HCFI) and Dr RN Tandon – Honorary Secretary General IMA in a joint statement, said " In India, we still rely heavily on insensitive diagnostic tools such as sputum smears. For the longest time, our TB programmes have ignored the TB patients in the private sector. There is a need to carry out nationwide prevalence surveys as India has been underestimating TB prevalence majorly. We must also ensure that those who need treatment have access to it no matter what corner of the country they are in." TB is a bacterial disease and spreads when an infected person coughs or sneezes. There are no obvious symptoms in a person infected with the bacteria that cause TB. In case symptoms do appear, they include cough (sometimes blood-tinged), weight loss, night sweats, and fever. TB is completely curable and preventable. Those with active TB symptoms require a long course of treatment involving consumption of multiple antibiotics. Adding further, Dr Aggarwal, said, "Some people can develop TB within a short time frame soon after they are infected and there are others, who can get sick much later. It is imperative to get treated for latent TB infection as about 5% to 10% of the infected people who do not receive treatment tend to develop the disease at some point in their lives. Those with a weak immune system need to be particularly careful." The following steps can be taken to reduce exposure to a person with TB in households. • Ventilate the house adequately • Educate the person on cough etiquette and respiratory hygiene. Encourage them to keep their mouth covered and maintain personal hygiene. • It is better for TB patients to not spend much time outdoors or in the public.

Sunday, 23 April 2017

New WHO ‘Global Hepatitis’ report highlights the impact of viral hepatitis

New WHO ‘Global Hepatitis’ report highlights the impact of viral hepatitis While the world focused on tackling the HIV/AIDS epidemic, another viral infection, viral hepatitis, has slowly gained foothold and has now become a major public health problem. This week, the World Health Organization (WHO) released a ‘Global Hepatitis’ report, which elaborates on the global burden of viral hepatitis and for the first time includes global and regional estimates on viral hepatitis in 2015. According to the report, globally, about 325 million people worldwide have chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Many among these are at risk of progression to chronic liver disease, cancer, and eventually death as they lack access to diagnostic tests and treatment. Viral hepatitis caused 1.34 million deaths in 2015, a number comparable to deaths caused by tuberculosis and higher than those caused by HIV. Of the five types of viral hepatitis, hepatitis B and C together account for 96% of overall mortality due to hepatitis. While deaths due to TB and HIV are declining, those due to viral hepatitis are increasing. Globally, countries in the WHO African and the Western Pacific Regions have the highest prevalence of hepatitis B. The WHO Eastern Mediterranean and the European Regions have the highest reported prevalence of hepatitis C. Here are some key points about viral hepatitis: • Hepatitis B is the most infectious of the three blood-borne viruses: Hepatitis B, hepatitis C and HIV. • Absence of jaundice does not rule out acute hepatitis infection, can just present with constitutional symptoms such as fever, vomiting, poor appetite, lethargy with high liver enzymes. • Because of their shared routes of transmission - infected body fluids such as blood, semen and vaginal fluid, or from a mother to her baby during pregnancy or delivery - people at risk for HIV infection are also at risk for HBV or HCV infection. • All people with HIV infection should be tested for hepatitis B and C infections. • Progression of liver disease is faster in viral hepatitis and HIV coinfection, which also increases the risk of serious, life-threatening health complications. • Hepatitis B can also be transmitted by fomites such as such as finger-stick devices used to obtain blood for glucose measurements, multi-dose medication vials, jet gun injectors, and endoscopes. • Hepatitis B is 10 times more infectious than HCV and 50–100 times more infectious than HIV. The HBV can survive in dried blood for up to 7 days and remains capable of causing infection. This makes hepatitis B a more dangerous infection than HIV. • Hence, any blood spills from a person with hepatitis B should be cleaned up with appropriate infection control procedures e.g. wearing gloves, and using an appropriate cleaning product for the surface, such as diluted bleach or detergent and warm water • The first step after being exposed to blood or bodily fluids is to wash the area well with soap and water and covered with a waterproof dressing or plaster. Expressing fluid by squeezing the wound will not reduce the risk of blood-borne infection. All unvaccinated persons should be administered hepatitis B vaccine after exposure to blood. If the exposed blood is positive for HBV and the exposed person is unvaccinated, treatment with hepatitis B immune globulin is recommended. • Hepatitis C virus can survive on environmental surfaces for up to 16 hours. It can also spread from infected fluid splashes to the conjunctiva. Dr KK Aggarwal National President IMA & HCFI

Thursday, 20 April 2017

A World Liver Day Initiative

A World Liver Day Initiative Excess alcohol bad for the liver • On World Liver Day, IMA warns that excess alcohol is responsible for fatty liver disease in a majority of people • Lifestyle changes key to a healthy liver New Delhi, 19th April 2017: Recent WHO (World Health Organization) statistics indicate that every year, about 2 lakh people die of liver ailments around the world. As per data, fatty liver disease is the third most common cause of chronic liver disease and affects 1 in 6 individuals. Just like the brain and heart, the liver is also a crucial organ that needs to be taken care of, more so if you are a heavy drinker. It has been found that about 25,000 lives can be saved by a liver transplant. However, data shows that at present, only 1,800 liver transplants happen every year globally. As in every year, 19th April is being celebrated as the World Liver Day this year as well. The liver has a very important role in the body’s digestive system. Speaking about this, Padma Shri Awardee Dr K K Aggarwal, National President Indian Medical Association (IMA) and President Heart Care Foundation of India (HCFI) and Dr RN Tandon – Honorary Secretary General IMA in a joint statement, said, "Anything that we eat or drink, including medication, must pass through the liver. It is the second-largest organ in the body and helps filter chemicals like drugs and alcohol from the blood; regulates hormones and blood sugar levels; stores energy from the nutrients and makes blood proteins, bile and several enzymes that the body needs. Keeping the liver healthy therefore is all about a healthy lifestyle. The basic thing about taking care of the liver is to avoid what’s bad rather than eat or drink something that nourishes this organ. Alcohol does more damage to the liver cells than one can imagine. It leads to swelling or scarring, later turning into cirrhosis, and can prove fatal to life." Alcoholic cirrhosis is the most common cause of cirrhosis, accounting for 40% of liver deaths from cirrhosis. The liver helps to remove alcohol from the blood through oxidation. However, once too much alcohol has been ingested for the liver to process in a well-timed manner, the toxic substance begins to turn into 'fatty liver'. This then is the early stage of alcoholic liver disease and can be seen in about 90% of people who drink more than two ounces (60 ml) of alcohol per day. Continuing to drink similar quantities of alcohol can lead to liver fibrosis and ultimately cirrhosis. Dr K K Aggarwal adds, "Fatty liver is reversible with timely medical intervention. However, it is also important to bring about certain lifestyle changes. If ignored, this condition can cause irreversible damage with liver transplant as the only end option. Therefore, it is important to avoid intake of alcohol, eat healthy, and get regular exercise. Timely hepatitis vaccines should also be considered to avoid any sort of complications to the liver." It is important to take care of the following points to keep the liver healthy. • Eat a healthy balanced diet and exercise regularly. • Eat out of all food groups, for instance, grains, protein, dairy products, fruits, vegetables, and fats. Eat fibrous food such as fresh fruits and vegetables, whole grain breads, rice, and cereals. • Avoid consuming alcohol, smoking, and drugs. They can permanently damage the liver cells. • Always make sure to consult your doctor before starting a new medication. Taking incorrect combinations of medicines can lead to liver damage. • Chemicals like aerosols and cleaning products can injure liver cells and therefore it is better to avoid extensive contact with these. • Keep a check on your weight as obesity can cause non-alcoholic fatty liver disease.

Friday, 17 March 2017

Write NLEM drugs

Write NLEM drugs The World Health Organization (WHO) has defined ‘essential medicines’ as those that satisfy the priority health care needs of the population. The WHO also says that the essential medicines should be available “at all times in adequate amounts, in the appropriate dosage forms, with assured quality, and at a price the individual and the community can afford”. 
The Alma Ata Declaration adopted by the World Health Assembly in 1978 was the first international declaration, a milestone, which brought primary health care to the forefront. It outlined provision of essential drugs as one of the essential components of primary health care. In the same year, the World Health Assembly passed a Resolution urging Member States to establish national lists of essential medicines and adequate procurement systems. 
India too joined hands with the WHO and the first National Essential Drugs List was published in 1996. It was revised in 2003 as the National List of Essential Medicines (NLEM). The latest revision was notified on December 23, 2015. The NLEM 2015 includes 376 medicines listed according to the level of health care: Primary, secondary and tertiary
Many criteria are considered to include a drug in the NLEM. • The medicine should be approved/licensed in India. • The medicine should be useful in disease which is a public health problem in India. • The medicine should have proven efficacy and safety profile based on valid scientific evidence. • The medicine should be cost effective. • The medicine should be aligned with the current treatment guidelines for the disease. • The medicine should be stable under the storage conditions in India. • When more than one medicine are available from the same therapeutic class, preferably one prototype/ medically best suited medicine of that class to be included after due deliberation and careful evaluation of their relative safety, efficacy, cost-effectiveness. • Price of total treatment to be considered and not the unit price of a medicine. • Fixed Dose Combinations (FDCs) are generally not included unless the combination has unequivocally proven advantage over individual ingredients administered separately, in terms of increasing efficacy, reducing adverse effects and/or improving compliance Essential drugs satisfy the priority healthcare needs of the large majority of the community. And, if a drug is listed in the essential medicines list, this means that it has to be “affordable, available at all times in adequate amounts with assured quality to meet the health care needs”. The NLEM assumes particular importance to India where out of pocket expenditure on health care is quite high and only a few have health insurance. 
An article published in the February 2015 issue of the Indian Journal of Medical Research says “Healthcare access in India is affected with 70:70 paradox; 70 per cent of healthcare expenses are incurred by people from their pockets, of which 70 per cent is spent on medicines alone, leading to impoverishment and indebtedness.” 
The United Nations Sustainable Development Goal (SDG) 3 “Ensure healthy lives and promote well-being for all at all ages” has outlined access to safe, effective, quality and affordable essential medicines for all in Target 3.8, which states: “Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.”
IMA believes that health care should be within reach of every person in the country. It should be affordable, with provisions for people from all economic strata. IMA is also committed to the 17 SDGs and their 169 targets. 
Hence, IMA recommends that its members should write NLEM drugs, instead of prescribing expensive non NLEM drugs to those who cannot afford them. But, this does not mean that drugs not included in the NLEM are non-inferior drugs. If you prescribe a non-NLEM and more expensive drug, explain to the patient why you are doing so.

Friday, 22 July 2016

WHO encourages countries to act now to reduce deaths from viral hepatitis

WHO encourages countries to act now to reduce deaths from viral hepatitis

Dr K K Aggarwal Ahead of World Hepatitis Day falling on 28th July 2016, WHO is urging countries to take rapid action to improve knowledge about the disease, and to increase access to testing and treatment services. Today, only 1 in 20 people with viral hepatitis know they have it. And just 1 in 100 with the disease is being treated. Around the world 400 million people are infected with hepatitis B and C, more than 10 times the number of people living with HIV. An estimated 1.45 million people died of the disease in 2013 – up from less than a million in 1990. “The world has ignored hepatitis at its peril,” said Dr Margaret Chan, WHO Director-General. “It is time to mobilize a global response to hepatitis on the scale similar to that generated to fight other communicable diseases like HIV/AIDS and tuberculosis.” In May 2016, at the World Health Assembly, 194 governments adopted the first ever Global Health Sector Strategy on viral hepatitis and agreed to the first-ever global targets. The strategy includes a target to treat 8 million persons for hepatitis B or C by 2020. The longer term aim is to reduce new viral hepatitis infections by 90% and to reduce the number of deaths due to viral hepatitis by 65% by 2030 from 2016 figures. As of 2014, 184 countries vaccinate infants against hepatitis B as part of their vaccination schedules and 82% of children in these states received the hepatitis B vaccine. This is a major increase compared with 31 countries in 1992, the year that the World Health Assembly passed a resolution to recommend global vaccination against hepatitis B. (Source: WHO, 20 July 2016)